Related Experiment Video
Updated: Jun 21, 2026
08:24
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
A cellular model to monitor proteasome dysfunction by alpha-synuclein
Takashi Nonaka1, Masato Hasegawa
1Department of Molecular Neurobiology, Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156-8585. nonakat@prit.go.jp
Biochemistry
|July 28, 2009
Summary
Impaired proteasome activity, linked to neurodegenerative diseases, is affected by alpha-synuclein. This study shows alpha-synuclein inhibits proteasome function, suggesting a new therapeutic target for conditions like Parkinson's disease.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Impairment of the ubiquitin-proteasome system is implicated in neurodegenerative diseases like Alzheimer's and Parkinson's.
- Alpha-synuclein is a key protein implicated in Parkinson's disease pathogenesis.
- Understanding the interaction between alpha-synuclein and cellular degradation pathways is crucial.
Purpose of the Study:
- To investigate the effect of intracellular alpha-synuclein on proteasome activity in neuronal cells.
- To determine if alpha-synuclein's filament-forming propensity influences its impact on proteasome function.
- To establish a cellular model for screening compounds that counteract alpha-synuclein-induced proteasome dysfunction.
Main Methods:
- Utilized a reporter system (GFP-CL1) to monitor intracellular proteasome activity in SH-SY5Y cells.
- Coexpressed wild-type and mutant forms of alpha-synuclein with the reporter.
- Analyzed proteasome activity using confocal microscopy and immunoblotting.
- Tested compounds that inhibit alpha-synuclein filament formation in vitro.
Main Results:
- Coexpression of alpha-synuclein significantly increased the level of intact GFP-CL1, indicating proteasome inhibition.
- Pathogenic and phosphomimetic mutants of alpha-synuclein showed a stronger inhibitory effect than wild-type.
- Alpha-synuclein's ability to inhibit proteasome activity correlated with its propensity to form filaments.
- Compounds inhibiting alpha-synuclein filament formation also prevented proteasome dysfunction in cells.
Conclusions:
- Intracellular alpha-synuclein impairs proteasome activity in a manner related to its filament assembly.
- The cellular model developed is a valuable tool for screening neuroprotective compounds.
- Targeting alpha-synuclein-mediated proteasome dysfunction may offer a therapeutic strategy for neurodegenerative diseases.
More Related Videos
Related Concept Videos
01:13The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...